FindTrial
Sign In

Genetic mutations associated with head and neck tumor immunity (CPS/TMB) were retrospectively analyzed based on second-generation sequencing

Genetic mutations associated with head and neck tumor immunity (CPS/TMB) were retrospectively analyzed based on second-generation sequencing

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104117
Enrollment
Unknown
Registered
2025-06-11
Start date
2025-06-12
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and neck tumors

Interventions

CPS positive(or TMB-H):NA

Sponsors

Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Solid tumors occurring in the head and neck, clinically diagnosed as squamous cell carcinoma, mucinous adenocarcinoma, etc. 2.Patients who have undergone NGS testing in the Cell and Molecular Diagnostic Center of our hospital and have passed the quality control of NGS data; 3.Genetic testing items: 520 or 425 genes of pan-cancer species are high-throughput sequencing.

Exclusion criteria

Exclusion criteria: 1.Non-solid tumors: hematological tumors and lymphomas; 2.No NGS test or NGS test quality control fails; 3.Lack of clinical data, such as immunohistochemistry, drug therapy and tumor imaging.

Design outcomes

Primary

MeasureTime frame
CPS score ;TMB;—

Countries

China

Contacts

Public ContactYongsheng Huang

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

huangysh65@mail.sysu.edu.cn+86 20 34071966

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026